Navigation Links
Trubion Reports Re-treatment Results Following Phase 1/2a and Phase 2b Studies Evaluating TRU-015 for Rheumatoid Arthritis
Date:10/27/2008

e@trubion.com

http://www.trubion.com

Waggener Edstrom Worldwide Healthcare

Amy Petty

Senior Account Executive

(617) 576-5788

amyp@waggeneredstrom.com

TRBN-G


'/>"/>
SOURCE Trubion Pharmaceuticals Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Trubion Pharmaceuticals Wins Patent Opposition - Genentech / Biogen Idec European Patent Revoked
2. Trubion Pharmaceuticals to Present at Fall 2008 Morgan Stanley Global Healthcare Unplugged Conference in New York
3. Trubion Pharmaceuticals to Present at the 7th Annual Needham & Company Biotechnology & Medical Technology Conference
4. Trubion Announces Presentations at April/May Investor Conferences
5. Trubion Pharmaceuticals Inc. Reports Fourth-Quarter and Year-Ended 2007 Financial Results and Provides 2008 Financial Outlook
6. Trubion Pharmaceuticals to Present at the Lazard Capital Markets Healthcare Investor Conference
7. Trubion Pharmaceuticals Inc. Reports Third Quarter and Nine Months 2007 Financial Results
8. Trubion Pharmaceuticals Announces Upcoming Presentations at American College of Rheumatology Annual Scientific Meeting
9. Trubion Pharmaceuticals to Present at Upcoming Investor Conferences
10. BioCryst Reports Results From the First-Ever Completed Active-Controlled Phase 2 Study in Hospitalized Influenza
11. International Drug & Explosive Detection Firm Identa Corp Releasing: Jant Pharmacal Corporation Reports Successful Market Penetration of the Accutest(R) IDenta Co-brand in the United States and Oversees
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... , July 11, 2014 , ... part) in, into or from any jurisdiction where to do ... such jurisdiction.  Shire plc ("Shire" or the "Company") ... article this afternoon.  Shire confirms it has held a meeting ... made by Shire without the prior agreement or approval of ...
(Date:7/11/2014)... July 11, 2014 EPFL and ... the appointment of John P. Donoghue . The ... Geneva . The new Wyss ... in Geneva , has named as ... John P. Donoghue , founder of Brown University,s ...
(Date:7/11/2014)... 11, 2014 Cayenne Medical, Inc., ... in the soft tissue reconstruction segment, announced the ... for surgeries involving the shoulder and extremities. The ... novel, inserter-controlled deployment method. The unique delivery eliminates ... anchor pull-out, or anchor displacement (also commonly know ...
(Date:7/10/2014)... UK (PRWEB) July 10, 2014 ... 21st Century Medicine Forum on ‘Commercialising Longevity Research’ ... and entrepreneurs to the London Bioscience Innovation Center ... Research Foundation and Aging Analytics Ltd. The meeting ... investment in translational research for age-related disease, as ...
Breaking Biology Technology:Shire plc - Statement re: Media Speculation 2John P. Donoghue is Taking the Lead at the Wyss Center and is Appointed Professor at EPFL and University of Geneva 2John P. Donoghue is Taking the Lead at the Wyss Center and is Appointed Professor at EPFL and University of Geneva 3Cayenne Medical Launches SureLock™ All-Suture Anchor System for Shoulder and Extremity Surgery 2Cayenne Medical Launches SureLock™ All-Suture Anchor System for Shoulder and Extremity Surgery 3DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 2DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 3DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 4DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 5DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 6
... Therapeutics, LLC, a biopharmaceutical company focused on the ... a $55 million Series C financing. The financing ... development and healthcare investment firm. The company ... Phase III clinical development program for its lead ...
... widely used drugs, is also one of the trickiest to ... of serious problems when given the standard starting dose. , ... based on genetic information, an international research team has created ... the blood-thinning drug for each patient. , Three University ...
... Corporation (Nasdaq: PMD ) today announced fourth ... December 31, 2008. The Company also announced a ... of record as of March 6, 2009 to be ... the Company,s 50th consecutive quarterly dividend.The Company,s revenue for ...
Cached Biology Technology:Sopherion Therapeutics Secures $55 Million in Series C Funding 2Genetic information personalizes warfarin prescribing 2Genetic information personalizes warfarin prescribing 3Psychemedics Corporation Announces 2008 Year End Results 2Psychemedics Corporation Announces 2008 Year End Results 3Psychemedics Corporation Announces 2008 Year End Results 4Psychemedics Corporation Announces 2008 Year End Results 5
(Date:7/10/2014)... BLUE BELL, Pa. , July 2, 2014  Unisys ... The Netherlands , Unisys Nederland N.V., today announced that ... (DJI) to deliver, implement and manage a new Basic Provision ... . Unisys won the contract with a ... for identity management software. The term of the contract is ...
(Date:7/10/2014)... -- Research and Markets ( http://www.researchandmarkets.com/research/h7h8lq/gesture ) has ... Recognition & Touch-Less Sensing (2D, 3D, Ultrasonic, IR, ... to their offering http://photos.prnewswire.com/prnh/20130307/600769 ... Sensing Market to Grow Exponentially. Touch-less sensing applications ... companies were unable to leverage this technology due ...
(Date:7/10/2014)... 2014  Acuity Market Intelligence today released forecasts from "The ... that the global market for National Electronic ID (eID) programs ... During this time, the number of National eID cards in ... Asia , with its vast population, will dominate ... issued, while Europe trails a distant ...
Breaking Biology News(10 mins):Unisys Delivers New Basic Provision Biometrics Solution to Dutch Custodial Institutions Service 2Unisys Delivers New Basic Provision Biometrics Solution to Dutch Custodial Institutions Service 3Global Gesture Recognition & Touch-Less Sensing (2D, 3D, Ultrasonic, IR, Capacitive) Market - Forecasts to 2020 2National Electronic ID Programs Generate $54 Billion Between 2013 and 2018 with 3.5 Billion National eID Card Holders Worldwide 2
... Michigan have found a new potential benefit of a ... proteins in the brain. The aggregation of ... disease and other neurodegenerative conditions., A paper published recently ... Sciences explained how U-M Life Sciences Institute faculty ...
... March 5, 2013 UT Southwestern Medical Center scientists report ... model of an incurable human cancer. "To my knowledge, this ... defined malignant human cancer has been generated in which the formation ... in which blocking the pathway cures the mouse of the tumor," ...
... technology could soon experience a significant upgrade that would ... the development of a new key material by a ... Department of Biomedical Engineering at Texas A&M University. ... signals that can be used to produce an image, ...
Cached Biology News:Green tea extract interferes with the formation of amyloid plaques in Alzheimer's disease 2UT Southwestern scientists make mouse model of human cancer, demonstrate cure 2UT Southwestern scientists make mouse model of human cancer, demonstrate cure 3Texas A&M research contributes to improved ultrasound imaging 2
D.R. Harper (1993) • Includes: essential information on taxonomy, culture and safe handling of viruses, immunology, monoclonal antibodies, antivirals and vaccines....
...
Performance, mycoplasma, virus, and endotoxin tested. Collected from calves 14 days old or less...
...
Biology Products: